Quince Therapeutics (QNCX) Research & Development (2018 - 2026)
Quince Therapeutics (QNCX) posted quarterly Research & Development of $6.8 million for Q1 2026, down 15.96% year-over-year from $8.1 million in Q1 2025, and down 45.68% quarter-over-quarter from $12.6 million in Q4 2025.
Quince Therapeutics (QNCX) Research & Development (2018 - 2026) Analysis & Trends
Quince Therapeutics' Research & Development history runs 9 years deep, the most recent figure standing at $6.8 million for Q1 2026.
- In Q1 2026, Research & Development fell 15.96% year-over-year to $6.8 million; the TTM figure through Mar 2026 stood at $34.1 million (up 47.97% YoY), while the FY2025 annual figure was $35.4 million, up 90.33% from the prior year.
- Research & Development for Q1 2026 stood at $6.8 million, down from $12.6 million in the prior quarter.
- The five-year high for Research & Development was $12.8 million in Q1 2022, with the low at $1.4 million in Q2 2023.
- The 5-year median for Research & Development is $5.4 million (2024), against an average of $5.8 million.
- The sharpest annual moves came in 2022 and 2024: Research & Development plunged 82.54% in 2022, then surged 243.54% in 2024.
- Quince Therapeutics' Research & Development stood at $7.2 million in 2022, then sank by 52.32% to $3.4 million in 2023, then soared by 69.63% to $5.8 million in 2024, then jumped by 116.33% to $12.6 million in 2025, then plunged by 45.68% to $6.8 million in 2026.
- Business Quant data shows QNCX's Research & Development at $6.8 million in Q1 2026, $12.6 million in Q4 2025, and $8.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.80 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.53 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.33 Bn | 60.14 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 59.76 Bn | 54.62 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.84 Bn | 28.53 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.23 Bn | 9.84 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.46 Bn | - | 97.90 Mn |
| 10 | Quince Therapeutics | 200.91 Mn | 200.91 Mn | - | 5.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.85 Mn |
| Dec 31, 2025 | 12.60 Mn |
| Sep 30, 2025 | 8.08 Mn |
| Jun 30, 2025 | 6.55 Mn |
| Mar 31, 2025 | 8.15 Mn |
| Dec 31, 2024 | 5.83 Mn |
| Sep 30, 2024 | 4.92 Mn |
| Jun 30, 2024 | 4.15 Mn |
| Mar 31, 2024 | 3.70 Mn |
| Dec 31, 2023 | 3.43 Mn |
| Sep 30, 2023 | 1.43 Mn |
| Jun 30, 2023 | 1.35 Mn |
| Mar 31, 2023 | 3.23 Mn |
| Dec 31, 2022 | 7.20 Mn |
| Sep 30, 2022 | 2.45 Mn |
| Mar 31, 2022 | 12.76 Mn |
| Dec 31, 2021 | 15.21 Mn |
| Sep 30, 2021 | 14.04 Mn |
| Jun 30, 2021 | 14.72 Mn |
| Mar 31, 2021 | 16.82 Mn |